Pune-headquartered Serum Institute of India (SII) has already manufactured about 40 million doses of the COVID-19 vaccine. The manufacturing is completed under the at-risk production and license of stockpiling from the Drugs Controller General of India (DCGI). With assistance from the ICMR (Indian Council of Medical Research), the Serum Institute Of India will target early access of the vaccine for the country.
A few days back, Adar Poonawalla, CEO of SII, said that accessibility of a potential vaccine to fight the pandemic within the country may be possible early next year. He added that the vaccine will be available to distribute in January 2021 provided that, necessary approvals from the concerned authorities are availed on time.
The SII CEO mentioned that the trials conducted in the United Kingdom and India have been promising so far. The third phase of the trials is still under process and it’s vital to understand the behavior of the vaccine on a long-term basis. The vaccine needs to be proven satisfactorily on the immunogenic and efficacy heads. The final results of the third-phase trials will command the roll-out period of the vaccine.
ICMR and SII declared the execution of the 3rd-phase clinical trial registration process for the Indian vaccine Covishield. Phase 2/ Phase 3 clinical trials are being conducted over 15 centers across the nation by ICMR and SII jointly.
A master seed availed from Astrazeneca/Oxford University is being used to develop the Covishield vaccine. The UK-based vaccine ChAdOx1 nCoV-19 is under the last phase of human trials. The trials are conducted across various countries including Brazil, the USA, and South Africa. According to the Union Health Ministry, total COVID-19 cases have raised to 86,83,916 in the country. Whereas the death toll due to the pandemic rose to 1,28,121, and a total of 80,66,501 people have recovered successfully from the infection.